Clearmind Medicine Files PCT Patent for MEAI-PEA Obesity and MASLD Therapy
Clearmind Medicine published a PCT patent application for its non-hallucinogenic MEAI-PEA combination therapy targeting obesity and metabolic dysfunction-associated steatotic liver disease. The program addresses obesity in 890 million adults and MASLD affecting 30% of adults within a weight-loss drugs market projected at $226 billion by 2035.
1. Patent Publication
Clearmind Medicine has filed an international patent application under the PCT for its proprietary combination of MEAI and Palmitoylethanolamide. The application secures intellectual property rights for a non-hallucinogenic therapy aimed at obesity and metabolic dysfunction-associated steatotic liver disease.
2. Novel MEAI-PEA Combination Therapy
The therapy integrates Clearmind’s 5-methoxy-2-aminoindane (MEAI) with PEA licensed from NeuroThera Labs. Preclinical data suggest the combination may offer a safer, cost-effective alternative to GLP-1 agonists by promoting neuroplasticity without hallucinogenic effects.
3. Market Potential and Outlook
Obesity affects 890 million adults globally and MASLD impacts roughly 30% of the adult population. The weight-loss drugs market, valued at $37 billion in 2025, is forecast to reach $226 billion by 2035, highlighting the program’s significant commercial opportunity.